Trial
NCT04840199
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Merck Sharp & Dohme LLC
Condition
HIV Infections
Intervention
Letermovir Oral Tablet
Why stopped
Permanently closed to screening and accrual due to futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-04